Stockscreener 앱 받기
2.14
10.46%
-0.25
시간 외 거래:
2.13
-0.01
-0.47%
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
Head to Head Comparison: ADC Therapeutics (NYSE:ADCT) & Astellas Pharma (OTCMKTS:ALPMY) - Defense World
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26% - Simply Wall St
Redmile Group, LLC Reduces Stake in ADC Therapeutics SA - GuruFocus.com
ADC Therapeutics shareholders approve capital increase - Investing.com India
Prosight Management, LP Expands Stake in ADC Therapeutics SA - GuruFocus.com
ADC Therapeutics SA (NYSE:ADCT) Q3 2024 Earnings Call Transcript - Insider Monkey
ADC Therapeutics : Guggenheim Healthcare Innovation Conference - Marketscreener.com
Analysts Set ADC Therapeutics SA (NYSE:ADCT) PT at $8.25 - Defense World
ADC Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% UpsideHere's Why - AOL
ADC Therapeutics SA (NYSE:ADCT) Receives $8.25 Average Price Target from Analysts - MarketBeat
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update - Marketscreener.com
ADC Therapeutics (NYSE:ADCT) Now Covered by Analysts at Stephens - MarketBeat
Stephens & Co. Initiates Coverage of ADC Therapeutics (ADCT) with Overweight Recommendation - MSN
ADC Therapeutics SA (ADCT) Quarterly 10-Q Report - Quartzy
ADC Therapeutics SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
ADC Therapeutics SA Reports Q3 2024: EPS of -$0.42 Misses Estima - GuruFocus.com
What To Expect From ADC Therapeutics SA (ADCT) Q3 2024 Earnings - GuruFocus.com
ADC Therapeutics : 3Q 2024 Earnings Call Presentation - Marketscreener.com
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting - The Malaysian Reserve
ADC Therapeutics' ZYNLONTA Shows 97% Response Rate in Lymphoma Clinical Trials | ADCT Stock News - StockTitan
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - MSN
ADC Therapeutics to Present at November 2024 Investor Conferences - BioSpace
ADC Therapeutics to Present at November Investor Conferences - The Malaysian Reserve
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - The Malaysian Reserve
ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 (PR Newswire) - Aktiellt
ADC Therapeutics (ADCT) Set to Announce Earnings on Thursday - MarketBeat
Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024 - GlobeNewswire Inc.
ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 - The Malaysian Reserve
Institutional investors own a significant stake of 32% in ADC Therapeutics SA (NYSE:ADCT) - Yahoo Finance
Global Antibody-Drug Conjugate Market Set for a ~USD 26 Billion Surge by 2030 | DelveInsight - The Malaysian Reserve
Antibody-Drug Conjugates Market to Grow at 28.4% CAGR from 2024 to 2029 - PR Newswire UK
The Manufacturers Life Insurance Company Purchases Shares of 26,938 ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA (NYSE:ADCT) Sees Large Growth in Short Interest - MarketBeat
Adc Therapeutics SA’s Shares Reel: -23.19% Quarterly Revenue Decline Amid 297.81M Market Cap - The InvestChronicle
Adc Therapeutics SA (ADCT) rating initates by Cantor Fitzgerald - Knox Daily
ADC Therapeutics SA's (NYSE:ADCT) institutional investors lost 10% over the past week but have profited from longer-term gains - Simply Wall St
Antibody Drug Conjugates Industry Report (2024-2032) - GlobeNewswire
Antibody Drug Conjugates Industry Report (2024-2032) Featuring Profiles the Top 13 PlayersADC Therapeutics, Astellas Pharma, AstraZeneca, Celldex Therapeutics, Roche & More - 24matins.uk
ADC Therapeutics : Subgroup analyses include patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients older than 65 (Form 6-K) - Marketscreener.com
Antibody Drug Conjugates Market Advancements Highlighted by Research 2024-2033 – Outlook, Overview - WhaTech
ADC Therapeutics SA (NYSE:ADCT) Shares Bought by XTX Topco Ltd - Defense World
Rhumbline Advisers Purchases Shares of 85,977 ADC Therapeutics SA (NYSE:ADCT) - Defense World
Adc Therapeutics (ADCT) Price Target Increased by 9.79% to 8.77 - MSN
Wall Street SWOT: ADC Therapeutics stock faces challenges amid potential growth - Investing.com India
3.66%
1.11%
자본화:
|
볼륨(24시간):